Mean age (y) | 59.6±10.4 | 60.1±8.7 |
Men, n (%) | 68 (80) | 29 (90.6%)* |
Body mass index, kg/m2 | 27.7±2.3 | 27.7±2.6 |
Family history of coronary artery disease, n (%) | 32 (37.6) | 21 (65.6)** |
Smoking, n (%) | 49 (57.6) | 25 (78.1)* |
Dyslipidemia, n (%) | 58 (68.2) | 22 (68.6) |
History of myocardial infarction, n (%) | 7 (8.2) | 4 (12.5) |
History of hypertension, n (%) | 68 (80) | 23 (71.9) |
Diabetes mellitus type 2, n (%) | 9 (10.6) | 5 (15.6) |
Previous antiplatelet intake, n (%) | 21 (24.7) | 7 (21.9) |
Mean level of troponin, ng/mL | 23.7 (0.3; 3.9) | 16 (0.4; 27.9) |
Localization of myocardial infarction |
Myocardial infarction of the anterior wall of LV, n (%) | 45 (52.9) | 16 (50) |
Myocardial infarction of the inferior wall of LV, n (%) | 36 (42.4) | 14 (43.8) |
Circumferential myocardial infarction, n (%) | 4 (4.7) | 2 (6.2) |
Characteristics of TLT |
’Pain-TLT’ interval, min (Ме (Q 25%; Q 75%)) | 180 (120; 240) | 120 (90; 180) |
TLT with alteplase, n (%) | 35 (41.2) | 12 (37.5) |
TLT with tenecteplase, n (%) | 15 (17.6) | 6 (18.8) |
TLT with pro-urokinase, n (%) | 35 (41.2) | 14 (43.7) |
Class of heart failure according to the Killip classification |
1, n (%) | 69 (81.2) | 24 (75) |
2, n (%) | 7 (8.2) | 2 (6.3) |
3, n (%) | 4 (4.7) | 3 (9.4) |
4, n (%) | 5 (5.9) | 3 (9.4) |